Neuropsychiatric Adverse Events and Oseltamivir for Prophylaxis Reply

被引：0
|
作者：
Toovey, Stephen [1 ]
机构：
[1] F Hoffmann La Roche Ltd, Basel, Switzerland
来源：
DRUG SAFETY | 2012年 / 35卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：1188 / 1190
页数：3
相关论文
共 50 条
  • [21] Comment on: Risk of neuropsychiatric adverse events associated with the use of oseltamivir: a nationwide population- based case-crossover study
    Ohkusa, Yasushi
    Sugawara, Tamie
    Taniguchi, Kiyosu
    Miyazaki, Chiaki
    Momoi, Mariko Y.
    Okabe, Nobuhiko
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (06) : 1762 - 1764
  • [22] Varenicline and the Evaluation of Neuropsychiatric Adverse Events in Smokers
    O'Malley, Stephanie S.
    BIOLOGICAL PSYCHIATRY, 2011, 69 (11) : 1017 - 1018
  • [23] Pharmacogenetics of dolutegravir and bictegravir neuropsychiatric adverse events
    Hoffmann, Christian
    MacKay, Alice
    Schewe, Carl Knud
    Hansen, Stefan
    Buhk, Thomas
    Fenske, Stefan
    Stellbrink, Hans-Juergen
    Adam, Axel
    Sabranski, Michael
    Boffito, Marta
    Owen, Andrew
    Elliot, Emilie
    INFECTION, 2021, 49 (SUPPL 1) : S21 - S22
  • [24] Varenicline, Smoking Cessation, and Neuropsychiatric Adverse Events
    Gibbons, Robert D.
    Mann, J. John
    AMERICAN JOURNAL OF PSYCHIATRY, 2013, 170 (12): : 1460 - 1467
  • [25] Adverse neuropsychiatric events associated with dexfenfluramine and fenfluramine
    McCann, UD
    Eligulashvili, V
    Ricaurte, GA
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1998, 22 (07): : 1087 - 1102
  • [26] Neuropsychiatric adverse events in brodalumab psoriasis studies
    Lebwohl, Mark
    Papp, Kim A.
    Wu, Jashin
    Blauvelt, Andrew
    Menter, Alan
    Rastogi, Shipra
    Israel, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB178 - AB178
  • [27] Dolutegravir and neuropsychiatric adverse events: a continuing debate
    Cailhol, Johann
    Rouyer, Cile
    Alloui, Chakib
    Jeantils, Vincent
    AIDS, 2017, 31 (14) : 2023 - 2024
  • [28] The impact of pediatric adverse events on the cost-effectiveness of oseltamivir
    Lavelle, T. A.
    Uyeki, T. M.
    Prosser, L.
    VALUE IN HEALTH, 2008, 11 (03) : A97 - A97
  • [29] Adverse events in the prophylaxis of haemophilia - Discussion
    Fischer, K
    Kilcoyne, R
    Blanchette, V
    Morfini, M
    Berntorp, E
    Manco-Johnson, M
    Schramm, W
    HAEMOPHILIA, 2003, 9 : 55 - 56
  • [30] Antibacterials for anthrax prophylaxis: adverse events
    Reactions Weekly, 2002, 884 (1) : 2 - 2
12345